MET and neoplasm: (59) found that the use of cabozantinib in vivo could inhibit c-Met and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) in osteoblasts, thereby reducing the expression of RANKL and M-CSF, and was associated with tumor-induced reduction of osteolysis.